Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rectal Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Rectal Cancer - Pipeline Review, H1 2015', provides an overview of the Rectal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Rectal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Rectal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rectal Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Rectal Cancer - Overview 8 Pipeline Products for Rectal Cancer - Comparative Analysis 9 Rectal Cancer - Therapeutics under Development by Companies 10 Rectal Cancer - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Rectal Cancer - Products under Development by Companies 14 Rectal Cancer - Companies Involved in Therapeutics Development 15 AbbVie Inc. 15 Apogenix GmbH 16 Cerulean Pharma, Inc. 17 GlaxoSmithKline plc 18 Hanwha Chemical Corporation 19 Incuron, LLC 20 Karyopharm Therapeutics, Inc. 21 Nanobiotix 22 Peregrine Pharmaceuticals, Inc. 23 Regeneron Pharmaceuticals, Inc. 24 Synta Pharmaceuticals Corp. 25 Rectal Cancer - Therapeutics Assessment 26 Assessment by Monotherapy Products 26 Assessment by Target 27 Assessment by Mechanism of Action 29 Assessment by Route of Administration 31 Assessment by Molecule Type 33 Drug Profiles 35 APG-350 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 bavituximab - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 CRLX-101 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ganetespib - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 GSK-2256098 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 HD-204 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 mepacrine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 NBTX-IV - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 NBTXR-3 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 selinexor - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 veliparib - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ziv-aflibercept (recombinant) - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Rectal Cancer - Recent Pipeline Updates 67 Rectal Cancer - Dormant Projects 102 Rectal Cancer - Product Development Milestones 103 Featured News & Press Releases 103 Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 103 Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 103 Appendix 105 Methodology 105 Coverage 105 Secondary Research 105 Primary Research 105 Expert Panel Validation 105 Contact Us 106 Disclaimer 106
List of Tables Number of Products under Development for Rectal Cancer, H1 2015 8 Number of Products under Development for Rectal Cancer - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Rectal Cancer - Pipeline by AbbVie Inc., H1 2015 15 Rectal Cancer - Pipeline by Apogenix GmbH, H1 2015 16 Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 17 Rectal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 18 Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H1 2015 19 Rectal Cancer - Pipeline by Incuron, LLC, H1 2015 20 Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 21 Rectal Cancer - Pipeline by Nanobiotix, H1 2015 22 Rectal Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 23 Rectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 24 Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 25 Assessment by Monotherapy Products, H1 2015 26 Number of Products by Stage and Target, H1 2015 28 Number of Products by Stage and Mechanism of Action, H1 2015 30 Number of Products by Stage and Route of Administration, H1 2015 32 Number of Products by Stage and Molecule Type, H1 2015 34 Rectal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 67 Rectal Cancer - Dormant Projects, H1 2015 102
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
